Brief: UCB Annouces FDA Approval For Zilbrysq Autoinjector Self-Administration For Adults Living With Generalized Myasthenia Gravis
16/10/2026 06:06
BRIEF-UCB Annouces FDA Approval For Zilbrysq Autoinjector Self-Administration For Adults Living With Generalized Myasthenia Gravis Oct 16 (Reuters) - Ucb SA UCB.BR:
ANNOUNCES U.S. FDA APPROVAL FOR ZILBRYSQ (ZILUCOPLAN) AUTOINJECTOR SELF-ADMINISTRATION FOR ADULTS LIVING WITH GENERALIZED MYASTHENIA GRAVIS
PRIOR TO AUTOINJECTOR'S APPROVAL, ZILBRYSQ WAS AVAILABLE AS A SELF-ADMINISTERED PREFILLED SYRINGE (PFS)
EXPECTS AUTOINJECTOR TO BE AVAILABLE COMMERCIALLY IN Q1 2027
Source text: nPLX4555H6
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on UCB SA
See all newsUCB tops STOXX after guidance upgrade on better drug sales
UCB upgrades 2026 guidance on strong US Bimzelx sales (updated)
UCB upgrades 2026 guidance on strong US Bimzelx sales
Brief: UCB Eyes Low- To Mid-Forties FY Adjusted EBITDA Growth
Brief: UCB Annouces FDA Approval For Zilbrysq Autoinjector Self-Administration For Adults Living With Generalized Myasthenia Gravis